Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Spire Wealth Management

Spire Wealth Management trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,671 shares of the medical research company’s stock after selling 343 shares during the period. Spire Wealth Management’s holdings in Thermo Fisher Scientific were worth $922,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Thermo Fisher Scientific by 7.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 89,047 shares of the medical research company’s stock valued at $45,056,000 after purchasing an additional 6,419 shares in the last quarter. Chicago Partners Investment Group LLC lifted its position in Thermo Fisher Scientific by 11.2% during the third quarter. Chicago Partners Investment Group LLC now owns 604 shares of the medical research company’s stock valued at $279,000 after buying an additional 61 shares in the last quarter. Gradient Investments LLC grew its stake in Thermo Fisher Scientific by 8.6% during the third quarter. Gradient Investments LLC now owns 12,920 shares of the medical research company’s stock worth $6,539,000 after buying an additional 1,018 shares during the period. Parcion Private Wealth LLC raised its stake in shares of Thermo Fisher Scientific by 5.8% in the 3rd quarter. Parcion Private Wealth LLC now owns 787 shares of the medical research company’s stock valued at $398,000 after acquiring an additional 43 shares during the period. Finally, Arbor Capital Management Inc. ADV lifted its holdings in shares of Thermo Fisher Scientific by 8.3% during the 3rd quarter. Arbor Capital Management Inc. ADV now owns 2,053 shares of the medical research company’s stock valued at $958,000 after acquiring an additional 157 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $573.64 on Thursday. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The firm has a market cap of $218.97 billion, a price-to-earnings ratio of 36.80, a PEG ratio of 2.37 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The stock has a 50 day moving average of $575.72 and a 200-day moving average of $535.12.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Analyst Ratings Changes

A number of brokerages have commented on TMO. The Goldman Sachs Group boosted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. JPMorgan Chase & Co. upped their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Royal Bank of Canada lifted their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Raymond James upped their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Finally, Robert W. Baird cut their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $607.35.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,711 shares of company stock valued at $21,630,972. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.